Novartis to build new radioligand therapy manufacturing facility in Florida

USA—Pharmaceutical giant Novartis announces ambitious plans to build a cutting-edge radioligand therapy (RLT) manufacturing facility in Winter Park, Florida.

This project anchors the company’s sweeping USD 23 billion investment program in the United States, which it unveiled in April 2025.

The initiative promises to ramp up the supply of innovative RLT cancer treatments nationwide, bringing life-saving therapies closer to patients who need them most.

This new 35,000 square foot, purpose-built site represents Novartis’s fourth dedicated RLT facility.

Engineers and experts design it specifically to strengthen the company’s supply chain and production prowess.

In particular, it targets optimized delivery for patients across the Southeast United States, where quick access to these therapies can make all the difference.

Novartis highlights that its existing RLT production network already achieves over 99% on-time dose administration, a reliability record that underscores its commitment to seamless patient care.

At its core, radioligand therapy revolutionizes precision oncology as it pairs a molecule that homes in on tumors with a powerful radioisotope, delivering targeted radiation straight to cancer cells.

This smart approach spares healthy tissues from unnecessary damage, offering hope where traditional treatments fall short.

Because each dose requires custom preparation and rapid delivery, Novartis strategically locates facilities near clinics and major transport hubs.

Such proximity ensures patients receive their treatments without delay, maximizing effectiveness.

The US Food and Drug Administration (FDA) has already approved two Novartis radioligand therapies, with more candidates in the pipeline targeting various tumor types.

Novartis leverages its deep expertise to refine manufacturing processes, steadily increasing capacity while guaranteeing a steady flow of medicines to patients and healthcare providers alike.

Looking ahead, Novartis commits to further growth over the next five years.

In addition to the Florida site, the company pours resources into expansions at facilities in New Jersey and Indiana.

Just last November 2025, Novartis completed a new RLT facility in California, marking a major milestone.

Soon, it plans to launch a fifth US site, solidifying its leadership in this transformative field.

Novartis CEO Vas Narasimhan emphasizes the significance of the Florida project.

“Building this new facility marks an important step in fulfilling the promise of RLT for patients,” he states.

He further explains that radioligand therapy has reshaped cancer treatment paradigms, and the expanding US manufacturing network equips Novartis to deliver these vital medicines swiftly and dependably to those in need.